VivoSeq
Other

Mcrc

0

Pipeline Programs↗

2

Active Trials↗

2

Companies Involved↗

mCRC is an early-stage landscape with 0 programs across 2 companies. The most active players are Zhejiang Raygene Pharmaceuticals Co., Ltd, Takeda.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

29/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Z

Zhejiang Raygene Pharmaceuticals Co., Ltd

0 programs

PreclinicalTakeda logo

Takeda

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

14

clinical trials

Completed4 · 29%
Unknown status4 · 29%
Terminated2 · 14%
Withdrawn2 · 14%
Not yet recruiting1 · 7%
Active, not recruiting1 · 7%

Clinical Trials

Trial Activity

14 trials

Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy
Active, not recruiting·UUniversity of California, Irvine·Phase 1·NCT04868773·12 enrolled
Gossypol Acetate + FOLFIRI + Bev in mCRC With TP53-Mutant and LRPPRC Positive
Not yet recruiting·—·Phase 2·NCT07337551·20 enrolled
Zinc Supplement in Regorafenib Treated mCRC Patient
Completed·—·Phase 2·NCT03898102·65 enrolled
TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated mCRC
Completed·TTTY Biopharm·Phase 2·NCT03517618·41 enrolled
Escalated Dose of Irinotecan in mCRC
Completed·—·N/A·NCT02256800·213 enrolled
Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC
Completed·Takeda logoTakeda·Phase 3·NCT02394795·823 enrolled
Sym004 Versus Futuximab or Modotuximab in Patients With mCRC
Terminated·SSymphogen A/S·Phase 2·NCT03549338·2 enrolled
TATE and KN046 in MCRC
Terminated·ZZhejiang Raygene Pharmaceuticals Co., Ltd·Phase 2·NCT06834399·42 enrolled
Sym004 Versus TAS-102 in Patients With mCRC
Withdrawn·SSymphogen A/S·Phase 3·NCT03717038
Chemoembolisation With CPT11 Loaded DC Bead With Cetuximab and 5FU/LV in First Line in Patients With KRAS Wildtype mCRC
Withdrawn·UUniversitaire Ziekenhuizen KU Leuven·N/A·NCT01631539
Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRC
Unknown status·GGruppo Oncologico del Nord-Ovest·Phase 3·NCT02339116·654 enrolled
Safety of Cetuximab and Trifluridin Tipiracil as the Third-line Therapy in the RASwt mCRC
Unknown status·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 1·NCT05155124·6 enrolled
OPTIMOX1 in Chinese mCRC Patients
Unknown status·NNanjing Medical University·Phase 4·NCT01023633·300 enrolled
Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRC
Unknown status·LLudwig-Maximilians - University of Munich·Phase 3·NCT01249638·516 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)